Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice

Neuropharmacology

Volumn 53, Issue 5, 2007, Pages 643-656

  Fox, Meredith A ^a   Jensen, Catherine L ^a   Gallagher, Pamela S ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 Hydroxy l tryptophan (5 HTP); Serotonin 1a receptors (5 HT1A, Htr1a); Serotonin 2a receptors (5 HT2A, Htr2a); Serotonin 7 receptors (5 HT7, Htr7); Serotonin syndrome; Serotonin transporter (SERT) knockout mice

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 5 HYDROXYTRYPTOPHAN; CLORGYLINE; GLEMANSERIN; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RECEPTOR; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN TRANSPORTER; TRANYLCYPROMINE;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; HETEROZYGOTE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROTONIN SYNDROME; WILD TYPE;

5-HYDROXYTRYPTOPHAN; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOAMINE OXIDASE INHIBITORS; PIPERAZINES; PIPERIDINES; POLYMORPHISM, GENETIC; PYRIDINES; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN SYNDROME; TRANYLCYPROMINE;

EID: 34848871368     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.07.009     Document Type: Article

References (59)

1. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mossner R., Westphal H., and Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998) 649-655
2. Bert B., Fink H., Hortnagl H., Veh R.W., Davies B., Theuring F., and Kusserow H. Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT. Behav. Brain Res. 167 (2006) 328-341
3. Bill D.J., Knight M., Forster E.A., and Fletcher A. Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br. J. Pharmacol. 103 (1991) 1857-1864
4. Birdsall T.C. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern. Med. Rev. 3 (1998) 271-280
5. Blakely R.D., Berson H.E., Fremeau Jr. R.T., Caron M.G., Peek M.M., Prince H.K., and Bradley C.C. Cloning and expression of a functional serotonin transporter from rat brain. Nature 354 (1991) 66-70
6. Bonaventure P., Kelly L., Aluisio L., Shelton J., Lord B., Galici R., Miller K., Atack J., Lovenberg T.W., and Dugovic C. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther. 321 (2007) 690-698
7. Bouali S., Evrard A., Chastanet M., Lesch K.P., Hamon M., and Adrien J. Sex hormone-dependent desensitization of 5-HT1A autoreceptors in knockout mice deficient in the 5-HT transporter. Eur. J. Neurosci. 18 (2003) 2203-2212
8. Boyer E.W., and Shannon M. The serotonin syndrome. N. Engl. J. Med. 352 (2005) 1112-1120
9. Cuijpers P., and Smit F. Excess mortality in depression: a meta-analysis of community studies. J. Affect. Disord. 72 (2002) 227-236
10. Dunkley E.J., Isbister G.K., Sibbritt D., Dawson A.H., and Whyte I.M. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96 (2003) 635-642
11. Fabre V., Beaufour C., Evrard A., Rioux A., Hanoun N., Lesch K.P., Murphy D.L., Lanfumey L., Hamon M., and Martres M.P. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12 (2000) 2299-2310
12. Fox M.A., Jensen C.L., and Murphy D.L. Mediation of exaggerated serotonin syndrome-like behaviors and temperature responses in serotonin transporter knockout mice by 5-HT1A and 5-HT7 serotonin receptors: a possible model and mechanism for differential human vulnerability to the serotonin syndrome. Neuropsychopharmacology 31 (2006) S221-S222
13. Fox M.A., and Murphy D.L. Exaggerated serotonin syndrome in serotonin transporter knockout mice. Int. J. Neuropsychopharmacol. 9 (2006) S174-S175
14. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry. 59 (2006) 1046-1051
15. Gobbi G., Murphy D.L., Lesch K., and Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296 (2001) 987-995
16. Goodwin G.M., De Souza R.J., and Green A.R. The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology 24 (1985) 1187-1194
17. Goodwin G.M., De Souza R.J., and Green A.R. Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berlin) 91 (1987) 500-505
18. Goodwin G.M., De Souza R.J., Green A.R., and Heal D.J. The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology (Berlin) 91 (1987) 506-511
19. Goodwin G.M., De Souza R.J., Wood A.J., and Green A.R. The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berlin) 90 (1986) 488-493
20. Hagan J.J., Price G.W., Jeffrey P., Deeks N.J., Stean T., Piper D., Smith M.I., Upton N., Medhurst A.D., Middlemiss D.N., Riley G.J., Lovell P.J., Bromidge S.M., and Thomas D.R. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br. J. Pharmacol. 130 (2000) 539-548
21. Hedlund P.B., Huitron-Resendiz S., Henriksen S.J., and Sutcliffe J.G. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol. Psychiatry 58 (2005) 831-837
22. Holmes A., Li Q., Murphy D.L., Gold E., and Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2 (2003) 365-380
23. Homberg J.R., Olivier J.D., Smits B.M., Mul J.D., Mudde J., Verheul M., Nieuwenhuizen O.F., Cools A.R., Ronken E., Cremers T., Schoffelmeer A.N., Ellenbroek B.A., and Cuppen E. Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 146 (2007) 1662-1676
24. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., and Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46 (1994) 157-203
25. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., and Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78 (2006) 815-826
26. Isbister G.K., and Buckley N.A. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin. Neuropharmacol. 28 (2005) 205-214
27. Izumi T., Iwamoto N., Kitaichi Y., Kato A., Inoue T., and Koyama T. Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. Eur. J. Pharmacol. 532 (2006) 258-264
28. Jacobs B.L. An animal behavior model for studying central serotonergic synapses. Life Sci. 19 (1976) 777-785
29. Kalueff A.V., Fox M.A., Gallagher P.S., and Murphy D.L. Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. Genes Brain Behav. 6 (2007) 389-400
30. Kennett G.A., Dickinson S.L., and Curzon G. Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone. Eur. J. Pharmacol. 119 (1985) 143-152
31. Kim D.K., Tolliver T.J., Huang S.J., Martin B.J., Andrews A.M., Wichems C., Holmes A., Lesch K.P., and Murphy D.L. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 49 (2005) 798-810
32. Landry E.S., Lapointe N.P., Rouillard C., Levesque D., Hedlund P.B., and Guertin P.A. Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice. Eur. J. Neurosci. 24 (2006) 535-546
33. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
34. Li Q., Wichems C., Heils A., Lesch K.P., and Murphy D.L. Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J. Neurosci. 20 (2000) 7888-7895
35. Li Q., Wichems C., Heils A., Van De Kar L.D., Lesch K.P., and Murphy D.L. Reduction of 5-hydroxytryptamine (5-HT) (1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291 (1999) 999-1007
36. Li Q., Wichems C.H., Ma L., Van de Kar L.D., Garcia F., and Murphy D.L. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J. Neurochem. 84 (2003) 1256-1265
37. Lucki I., Nobler M.S., and Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J. Pharmacol. Exp. Ther. 228 (1984) 133-139
38. Mannoury la Cour C., Boni C., Hanoun N., Lesch K.P., Hamon M., and Lanfumey L. Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J. Neurosci. 21 (2001) 2178-2185
39. Martin K.F., Phillips I., Hearson M., Prow M.R., and Heal D.J. Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br. J. Pharmacol. 107 (1992) 15-21
40. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., and Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 140 (2004) 169-181
41. Montanez S., Owens W.A., Gould G.G., Murphy D.L., and Daws L.C. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J. Neurochem. 86 (2003) 210-219
42. Nisijima K., Yoshino T., and Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berlin) 150 (2000) 9-14
43. Nisijima K., Yoshino T., Yui K., and Katoh S. Potent serotonin (5-HT) (2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 890 (2001) 23-31
44. Pan Y., Gembom E., Peng W., Lesch K.P., Mossner R., and Simantov R. Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice. Brain Res. Dev. Brain Res. 126 (2001) 125-129
45. Perez X.A., and Andrews A.M. Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice. Anal. Chem. 77 (2005) 818-826
46. Prasad H.C., Zhu C.B., McCauley J.L., Samuvel D.J., Ramamoorthy S., Shelton R.C., Hewlett W.A., Sutcliffe J.S., and Blakely R.D. Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11545-11550
47. Qu Y., Villacreses N., Murphy D.L., and Rapoport S.I. 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology (Berlin) 180 (2005) 12-20
48. Ravary A., Muzerelle A., Darmon M., Murphy D.L., Moessner R., Lesch K.P., and Gaspar P. Abnormal trafficking and subcellular localization of an N-terminally truncated serotonin transporter protein. Eur. J. Neurosci. 13 (2001) 1349-1362
49. Shen H.W., Hagino Y., Kobayashi H., Shinohara-Tanaka K., Ikeda K., Yamamoto H., Yamamoto T., Lesch K.P., Murphy D.L., Hall F.S., Uhl G.R., and Sora I. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29 (2004) 1790-1799
50. Shioda K., Nisijima K., Yoshino T., and Kato S. Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28 (2004) 633-640
51. Smith L.M., and Peroutka S.J. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24 (1986) 1513-1519
52. Sternbach H. The serotonin syndrome. Am. J. Psychiatry. 148 (1991) 705-713
53. Thomas D.R., Atkinson P.J., Ho M., Bromidge S.M., Lovell P.J., Villani A.J., Hagan J.J., Middlemiss D.N., and Price G.W. [(3)H]-SB-269970-A selective antagonist radioligand for 5-HT(7) receptors. Br. J. Pharmacol. 130 (2000) 409-417
54. Thomas D.R., Melotto S., Massagrande M., Gribble A.D., Jeffrey P., Stevens A.J., Deeks N.J., Eddershaw P.J., Fenwick S.H., Riley G., Stean T., Scott C.M., Hill M.J., Middlemiss D.N., Hagan J.J., Price G.W., and Forbes I.T. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br. J. Pharmacol. 139 (2003) 705-714
55. Van Oekelen D., Megens A., Meert T., Luyten W.H., and Leysen J.E. Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats. Behav. Pharmacol. 13 (2002) 313-318
56. Wesolowska A., Nikiforuk A., and Stachowicz K. Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur. J. Pharmacol. 553 (2006) 185-190
57. Wesolowska A., Nikiforuk A., Stachowicz K., and Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51 (2006) 578-586
58. Wesolowska A., Tatarczynska E., Nikiforuk A., and Chojnacka-Wojcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT(7) receptor antagonist in the forced swimming test in mice. Eur. J. Pharmacol. 555 (2007) 43-47
59. Yamada J., Sugimoto Y., and Horisaka K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol. 154 (1988) 299-304